D G Sherman
Affiliation: University of Texas Health Science Center
- Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod TrialD G Sherman
Division of Neurology, University of Texas Health Science Center, San Antonio 78284 7883, USA
JAMA 283:2395-403. 2000....
- Antithrombotic therapy in the acute phase: new approachesD G Sherman
Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, TX 78299 3900, USA
Cerebrovasc Dis 11:49-54. 2001....
- The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparisonDavid G Sherman
Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
Lancet 369:1347-55. 2007..We aimed to compare the efficacy and safety of enoxaparin with that of unfractionated heparin for patients with stroke...
- Antithrombotic and hypofibrinogenetic therapy in acute ischemic stroke: what is the next step?David G Sherman
Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
Cerebrovasc Dis 17:138-43. 2004..Recent clinical trials have suggested that other antithrombotic agents may be beneficial in acute ischemic stroke. Two such agents are ancrod and abciximab. Abciximab is currently being investigated in a large randomized clinical trial...
- Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm controlDavid G Sherman
Division of Neurology Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
Stroke 38:615-7. 2007..All patients with atrial fibrillation at increased risk for stroke should be continued on long-term anticoagulation even if they appear to have been successfully restored to sinus rhythm...
- Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) studyDavid G Sherman
University of Texas Health Science Center, San Antonio, USA
Arch Intern Med 165:1185-91. 2005..The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study was a multicenter comparison of high-risk patients with AF who were randomized to either a sinus rhythm control or a rate control strategy...
- Lessons from the Stroke Prevention in Atrial Fibrillation trialsRobert G Hart
Department of Medicine Neurology, University of Texas Health Science Center, 7703 Floyd Curl Drive MC 7883, San Antonio, Texas 78229 3900, USA
Ann Intern Med 138:831-8. 2003..For patients at moderate risk for stroke, patient preferences and access to reliable anticoagulation monitoring are particularly relevant...
- AncrodDavid G Sherman
Department of Medicine, University of Texas Health Science Center, San Antonio 78229 3900, USA
Curr Med Res Opin 18:s48-52. 2002..The clinical studies of ancrod in patients with stroke have shown a benefit with ancrod treatment in neurological outcome with only a modest increase in bleeding risk...
- Reconsideration of TIA diagnostic criteriaDavid G Sherman
University of Texas at San Antonio Health Science Center, San Antonio, TX, USA
Neurology 62:S20-1. 2004
- Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status SubstudyMina K Chung
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Am Coll Cardiol 46:1891-9. 2005..The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) functional status substudy aimed to test the hypothesis that functional status is similar in rate-control and rhythm-control strategies...
- Safety and tolerability of arundic acid in acute ischemic strokeL Creed Pettigrew
Stroke Program, Sanders Brown Center on Aging, and Department of Neurology, 101 Sanders Brown Building, University of Kentucky Medical Center, Lexington, KY 40536 0230, USA
J Neurol Sci 251:50-6. 2006..023 vs. placebo), 7 (p=0.002), 10 (p=0.003), and 40 (p=0.018). A dose of 8 mg/kg/h AA produced a favorable trend in reduction of NIHSS that should be confirmed in a future clinical trial...
- Transient ischemic attack--proposal for a new definitionGregory W Albers
Stanford University School of Medicine Palo Alto, CA 94305, USA
N Engl J Med 347:1713-6. 2002